10 mg/ml
Trade Name
Ximluci
Solution for injection
Request Type
New Registration
Drug Type
Biological
Approval Date
SFDA Approved Use
Ranibizumab is intended for the following indications:
1.The treatment of neovascular (wet) age-related macular degeneration (AMD)
2.The treatment of visual impairment due to diabetic macular oedema (DME)
3.The treatment of proliferative diabetic retinopathy (PDR)
4.The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
5.The treatment of visual impairment due to choroidal neovascularisation (CNV)
1.The treatment of neovascular (wet) age-related macular degeneration (AMD)
2.The treatment of visual impairment due to diabetic macular oedema (DME)
3.The treatment of proliferative diabetic retinopathy (PDR)
4.The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
5.The treatment of visual impairment due to choroidal neovascularisation (CNV)